Temsirolimus as Second-line Therapy in HCC

NCT01567930 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Unresectable or Metastatic Hepatocellular Carcinoma

Interventions

DRUG: Temsirolimus

Sponsor

University of Tennessee Cancer Institute

Collaborators

[object Object]